|
|
|
| The Predictive Value of the Level of Serum S100B Protein Expression on the Risk of Brain Metastasis in Patients with Small Cell Lung Cancer |
| YAN Bo, MAO Xiaowei, ZHANG Wei, et al |
| Shanghai Chest Hospital of Shanghai Jiaotong University, Shanghai 200030, China |
|
|
|
|
Abstract Objective: To evaluate the predictive value of serum S100B expression in brain metastasis risk for patients with small cell lung cancer (SCLC) and its association with clinicopathological characteristics of SCLC patients. Methods: 20 SCLC patients with brain metastases, 24 SCLC patients without brain metastases and 16 post-operative SCLC patients as control group were enrolled in this case-control study. The serum levels of S100B in three groups were detected by ELISA. Results: Serum S100B levels in SCLC patients with brain metastases were markedly increased compared with SCLC patients without brain metastasis and postoperative SCLC patients (all P<0.001). Receiver Operating Characteristic (ROC) showed that serum S100B level had a good predictive value for brain metastasis in SCLC patients(SCLC patients with brain metastases vs. SCLC patients without brain metastases: AUC 0.840 (95% CI: 0.721~0.958); SCLC patients with brain metastases vs. post-operative SCLC patients: AUC 0.906 (95% CI: 0.811~1.000)). Multivariate regression analysis displayed that high level of serum S100B was an independent factor in predicting brain metastasis risk in SCLC patients (P=0.025). In addition, serum S100B level was positive associated with N stage in SCLC patients with brain metastases (P=0.019). Spearman rank correlation analysis revealed that serum S100B level was positively correlated with Neuron Specific Enolase (NSE) in SCLC patients with brain metastases (r=0.508, P=0.022). Conclusion: Serum S100B could be a promising biomarker of brain metastasis risk in SCLC patients, and it is positively correlated with N stage and NSE level in SCLC patients with brain metastasis.
|
|
|
|
|
|
[1] Van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer[J]. Lancet, 2011, 378(9804): 1741~1755.
[2] Baize N, Monnet I, Greillier L, et al. Second-line treatments of small-cell lung cancers[J]. Expert Rev Anticancer Ther, 2017, 17(11): 1033~1043.
[3] Lee SH. Role of chemotherapy on brain metastasis[J]. Prog Neurol Surg, 2012, 25: 110~114.
[4] Choi H, Puvenna V, Brennan C, et al. S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer[J]. Transl Lung Cancer Res, 2016, 5(4): 413~419.
[5] Wu L, Zhou X, Xiao Z, et al. Functional expression, characterization, and application of human S100B[J]. Oncol Rep, 2017, 38(4): 2309~2316.
[6] Kuwar RB, Stokic DS, Leis AA, et al. Does astroglial protein S100B contribute to West Nile neuro-invasive syndrome[J].Neurol Sci, 2015, 358(1-2): 243~252.
[7] Weide B, Richter S, Buttner P, et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy[J]. PLoS One, 2013, 8(11): e81624.
[8] Vogelbaum MA, Masaryk T, Mazzone P, et al. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage[J]. Cancer, 2005, 104(4): 817~824.
[9] Egberts F, Pollex A, Egberts JH, et al. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH[J]. Onkologie, 2008, 31(7): 380~384.
[10] Gu XH, Zhang G, Zhang XQ, et al. Clinical values of detection of serum levels of S100B and NSE in diagnosis of brain injuries at early period after cardiopulmonary bypass[J]. Zhonghua Yi Xue Za Zhi, 2007, 87(14): 975~977.
[11] Darlix A, Lamy PJ, Lopez-crapez E, et al. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases[J]. Int Cancer, 2016, 139(10): 2299~2311. |
|
|
|
2018, Vol. 24 
